CURRICULUM VITAE (CV ) Institutul Oncologic Al.Trestiorean u Bucuresti. Sept sept Specialist oncologie medicala

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "CURRICULUM VITAE (CV ) Institutul Oncologic Al.Trestiorean u Bucuresti. Sept sept Specialist oncologie medicala"

Transcription

1 CURRICULUM VITAE (CV ) 1. Nume: VOLOVAT 2. Prenume: CONSTANTIN 3. Data şi locul naşterii: 22 apr 1959, ROMAN, JUD.NEAMT 4. Cetăţenie: ROMANA 5. Stare civilă: CASATORIT 6. Studii: Instituţia Perioada: de la (luna, anul) până la (luna, anul) Grade sau diplome obţinute Univ. de Medicina si Farmacie GR.T.POPA IASI Sept.1979 Sept DOCTOR - MEDIC Institutul Oncologic Al.Trestiorean u Bucuresti Sept sept.1993 Specialist oncologie medicala Institutul Oncologic Al.Trestioreanu Bucuresti Univ. AL.I.CUZA IASI 1997 Mai mai 2004 Medic primar oncologie medicala 7. Titlul ştiinţific: doctorand UMF GR.T.POPA Indrumator Prof.dr. E.Zbranca 8. Experienţa profesională: Perioada: de la..(luna, anul) până la..(luna, anul) Sept dec Ian pana in prezent Locul: Policlinica judeteana Policlinica judeteana Instituţia: Funcţia: Descriere: Spitalul Univ. Sf.Spiridon Iasi Medic coordonator oncologie ambulatoriu jud. Iasi Profilaxie, diagnostic, tratament sistemic si dispensarizare in cancer Centrul de Oncologie Medicala Medic coordonator Profilaxie, diagnostic, tratament sistemic si dispensarizare in cancer Master in Servicii de Sanatate Publica 9. Locul de muncă actual şi funcţia: medic coordonator - Centrul de Oncologie Medicala SCM 10. Vechime la locul de muncă actual: 8 ANI 11. Brevete de invenţii: 12. Lucrări elaborate şi / sau publicate (se prezinta lista cuprinzand maxim 5 (cinci) lucrari in domeniul proiectului, relevante pentru activitatile ce urmeaza a fi desfasurate in cadrul proiectului): 13. Membru al asociaţiilor profesionale: - din 1997 membru fondator al Societatii Romane de Oncologie Medicala - din 2001 membru al American Society of Clinical Oncology (ASCO) 14. Limbi straine cunoscute: ENGLEZA, FRANCEZA 15. Specializări şi calificări: - februarie training - Royal Marsden Hospital, London Glioma Perceptorship Program - mai 1999 training - European School of Oncology, Vienna Training in clinical trials martie 2007 training Buna Practica in Studiul Clinic curs pentru investigatori si monitori Verumedu SRL

2 16. Experienţa acumulată (inclusiv experienta manageriala) în programe/proiecte naţionale/internaţionale: Programul/Proiectul Funcţia Perioada: de la... până la... Comisia Nationala de Oncologie Ministerul Sanatatii membru al Sub-comisiei de 1998 Statistica, Organizare si Baze de Date Ministerul Sanatatii consultant august mai Alte competenţe: 18. Alte menţiuni: Experienta ca Investigator Principal (P.I.) in Studii Clinice cu beneficiu terapeutic (de faza II- III) multicentrice, multinationale (aprobate de Agentia Nationala a Medicamentului si Comisia Nationala de Etica si desfasurate sub supravegherea FDA si EMEA) : 1). In colaborare cu OCC ( Compania de Cercetare Clinica) PAREXEL International Romania s.r.l phase II/III study - A double blind, randomized, parallel group, placebo controlled, comparative study of efficacy, safety and tolerability of cannabis based medicine extracts (CBME) in patients with cancer-related pain Protocol GWCA perioada - ianuarie 2003 martie pacienti randomizati 2.- phase II/III study Symptomatic malignant ascites using paracentesis plus the tri-functional antibody, - perioada octombrie.2004-noiembrie.2005, 4 pacienti randomizati; 3. phase II/III study Efficacy and safety of XM21 compared with filgrastim in patients with non-small cell lung cancer receiving chemotherapy with platinum compounds - perioada - decembrie 2004 mai 2005, 19 pacienti randomizati 4 - Phase II Study Comparing 5FU/FA Plus Oxaliplatin Plus Cetuximab vs 5-FU/FA Plus Oxaliplatin as First-Line Treatment for EGFR-Expressing Metastatic Colorectal Cancer - perioada - februarie.2006 mai 2006, 8 patienti randomizati; 5. - Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab vs. 5FU/FA Plus Irinotecan as First-Line Treatment for EGFR-Expressing Metastatic Colorectal Cancer - perioada august 2005 decembrie 2005, 9 patienti randomizati; 6.- Phase II Study Efficacy and safety of XM01 compared to placebo and Epoetin beta in patients with solid tumours receiving platinum containing chemotherapy - perioada - ianuarie 2006 august 2006, 25 pacienti randomizati 7.- Phase II Study - Efficacy and safety of XM01 compared to placebo and Epoetin beta in patients with solid tumours receiving non-platinum containing chemotherapy - perioada - ianuarie 2006 mai pacienti randomizati 2). In colaborare cu OCC ( Compania de Cercetare Clinica) WYETH International 1. - A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Oral CCI-779 (temsirolimus) Administered in Combination with Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer - Protocol Number 3066A1-303WW 2

3 - perioada ianuarie decembrie 2005, 12 pacienti randomizati 3). In colaborare cu OCC ( Compania de Cercetare Clinica) M&M Clinical Research Enterprise Ltd phase III study Symptomatic malignant ascites using paracentesis plus the tri-functional antibody - perioada octombie 2005-prezent, 9 patienti randomizati; 2. - A Phase III Clinical Study of treatment with Thym-Uvocal vs. Placebo in Metastatic Colorectal Carcinoma - perioada - octombrie 2005 februarie 2006, 7 pacienti randomizati 4). In colaborare cu OCC ( Compania de Cercetare Clinica) PSI PHARMA SUPPORT 1.- A Multicenter Phase 3, Randomized Comparison of the Safety and Efficacy of Weekly TOCOSOL(R) Paclitaxel vs. Weekly Paclitaxel Injection in the Treatment of Metastatic Breast Cancer - perioada - ian 2006 august 2006, 8 patienti randomizati; 2. Studiu de fază III, randomizat, controlat, asupra medicamentului picoplatin şi cea mai bună îngrijire medicală faţă de exclusiv cea mai bună îngrijire medicală la pacienţi cu cancer pulmonar cu celule mici, refractar sau progresiv în termen de şase luni de la încetarea chimioterapiei de prima linie pe bază de platină - debut apr pacienti randomizati 3. Protocolul KTN32313R Studiu de fază 3 asupra siguranţei şi eficacităţii tratamentului cu karenitecin faţă de topotecan administrate timp de 5 zile consecutiv o dată la 3 săptămâni pacientelor cu cancer ovarian epitelial în stadiu avansat - debut - dec ). In colaborare cu OCC ( Compania de Cercetare Clinica) JOHNSON & JOHNSON 1. - A Randomized Controlled Study of Docetaxel Monotherapy or DOXIL /CAELYX and Docetaxel for the Treatment of Advanced Breast Cancer - perioada - ianuarie.2006 sept.2006, 10 patienti randomizati; 2. - Phase III A Randomized, Open-Label, Multicenter Study Evaluating Thrombovascular Events in Subjects with Cancer Receiving Chemotherapy and Administered Epoetin Alfa Once or Three Times a Week for the Treatment of Anemia - perioada martie 2007 prezent, 4 pacienti randomizati 6). In colaborare cu OCC ( Compania de Cercetare Clinica) PRA INTERNATIONAL 3

4 1. - A Phse II Study for immunological evaluation, efficacy adn safety of treatment with HER 2 AUTO VAC Protein + STIMULON ADJUVANT QS-21 in monotherapy at pacients with metastatic breast cancer - Protocol PX perioada ian 2005 mai 2005, 2 paciente randomizate 2. - A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 vs Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes and Refractory to the Most Recent Chemotherapy - perioada - ianuarie prezent, 8 patienti randomizati; 3. - Phase II Once Per Cycle Treatment of Anemia With Darbepoetin Alfa With Iron in Subjects With Non Myeloid Malignancies - perioada - aprilie 2007 prezent, 11 patienti randomizati 4. - Phase III clinical study, START (Stimulating Targeted Antigenic Responses To NSCLC), assessing the efficacy and safety of Stimuvax (BLP25 liposome vaccine) as a potential treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC) - debut - iunie pacient randomizat 7). In colaborare cu OCC ( Compania de Cercetare Clinica) GLAXO SMITHKLINE 1. - Phase III Multicenter, Randomized, Double-Blind, Chemo-therapy-Induced Nausea and Vomiting in Cancer Subjects - perioada ianuarie 2007 prezent, 20 patienti randomizati; 2. - A Randomised Study, Open Label, multicentric, phase III, for comparing the activity of Lapatinib monotherapy, Trastuzumab monotherapy, sequential therapy with Trastuzumab followed by Lapatinib and concomitant treatment with Lapatinib and Trastuzumab, as adjuvant treatment in patients with breast cancer with hiperexpression of Erb B2 and/or Erb B2 amplification - Studiul Clinic EGF ALTTO - debut - iunie paciente randomizate 8). In colaborare cu OCC ( Compania de Cercetare Clinica) PHARMANET ROMANIA 1.- Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with Breast Cancer - perioada mai 2007 pana in prezent, 1 pacienta randomizata 2. CT 4002 An open-label, randomized, controlled Phase-II trial evaluating the efficacy and safety of EndoTAG-1 in triple receptor negative breast cancer patients - debut ian ). In colaborare cu OCC ( Compania de Cercetare Clinica) COVANCE ROMANIA 1.- A Phase III, multicenter,placebo-controlled, double blind, randomised clinical trial to evaluate the efficacy of Bevacizumab in combination with Tarceva compared with Tarceva alone 4

5 for treatment of Advanced No-Small Cell Lung Cancer, after Failure of Standard first line chemotherapy (Studiul ATLAS si Studiul BETA) - debut iunie pacienti randomizati 2. A phase II Biomarker Identification Trial for Erlotinib (Tarceva ) in Patients with Advanced Pancreatic Carcinoma. - debut feb ). In colaborare cu OCC SANOFI-AVENTIS A Multinational, Randomized, Double-blind Study Comparing the Efficacy of Aflibercept Once every 2 weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer Patient (MPC) (VANILLA ) -debut feb ). In colaborare cu OCC ( Compania de Cercetare Clinica) KENDLE ROMANIA 1. A Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas - debut ian ). In colaborare cu OCC ( Compania de Cercetare Clinica) CLINICAL TRIALS COMPANY 1. Protocol GCF071 Titlu: Studiu faza III randomiz.,multicentric,dublu-orb,de echivalenta terapeutica intre G- CSF(Pliva/Mayne Filgrastim ) versus Neupogen (filgrastim Amgen) la subiecti aflati in tratament cu docetaxel-doxorubicin pentru cancer de san - Debut octombrie paciente randomizate 13). In colaborare cu OCC ( Compania de Cercetare Clinica) KOSAN BIOSCIENCE 1. Phase 2 Clinical Trial of Intravenous Alvespimycin (KOS-1022) in Patients with Her2 Positive Breast Cancer - debut - dec ). In colaborare cu OCC ( Compania de Cercetare Clinica) - i3 1. A Multicentre, Open-Label, Extension Study to Investigate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) for the Treatment of Breakthrough Cancer Pain in Subjects with Malignancies - debut dec ). In colaborare cu OCC ( Compania de Cercetare Clinica) INC RESEARCH 1. An Open-label, Sequential, Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Fixed, Repeated Doses of NE-180 (GlycoPEGylated rhuepo) in Anemic Cancer Patients Receiving Chemotherapy Protocol No.: NE debut dec pacienti randomizati 5

6 PUBLICATII CORELATE CU PROIECTUL 1. International Classification of Diseases for Oncology ICD-O World Health Organisation 2000, membru in colectivul de traducere in limba romana Alte lucrari in curs de prezentare (ASCO 2008) la adresele : 022CE8C%2DA769%2D4C00%2DBC07%2D E8E2%7D&Ckey=%7BD4CF6F59%2DCAEE%2D4B55%2D A27D%2D39BA767F0867%7D 022CE8C%2DA769%2D4C00%2DBC07%2D E8E2%7D&Ckey=%7BC255444C%2D771B%2D4D0D%2D A740%2DED41C9C1FD90%7D 6

General Surgeon Assistant Professor Gr.T. Popa University of Medicine and Pharmacy Department of Surgery, Saint Spiridon Hospital, Iasi, Romania

General Surgeon Assistant Professor Gr.T. Popa University of Medicine and Pharmacy Department of Surgery, Saint Spiridon Hospital, Iasi, Romania CURRICULUM VITAE Liviu Paul LEFTER General Surgeon, MD, PhD Date and place of Birth: 13 th of September 1970, Romania Nationality: Romanian Current Position General Surgeon Assistant Professor Gr.T. Popa

More information

National Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007

National Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007 Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature

More information

An D. Nguyen, MD Curriculum Vitae

An D. Nguyen, MD Curriculum Vitae OFFICE/ BUSINESS ADDRESS: Pacific Shores Medical Group 19582 Beach Blvd, Suite 212 Huntington Beach, CA 92648 Phone: (714) 252-9415 Fax: (714) 963-8407 ADDITIONAL OFFICE: 16300 Sand Canyon Avenue, Suite

More information

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved

More information

CURRICULUM VITAE. Vereanu Anca Delia. Adresa: Str. Erou Iancu Nicolae 67 B, Data nasterii : 31 iulie Nationalitatea : Romana

CURRICULUM VITAE. Vereanu Anca Delia. Adresa: Str. Erou Iancu Nicolae 67 B, Data nasterii : 31 iulie Nationalitatea : Romana CURRICULUM VITAE Vereanu Anca Delia Adresa: Str. Erou Iancu Nicolae 67 B, Vila 7, Voluntari, Ilfov Data nasterii : 31 iulie 1967 Nationalitatea : Romana Statut civil: Casatorita Telefon mobil: +40 722

More information

National Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007

National Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007 Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not

More information

Asociatia pentru Servicii Mobile de Ingrijire Paliativa in 2010

Asociatia pentru Servicii Mobile de Ingrijire Paliativa in 2010 de Ingrijire Paliativa in 2010 Echipa SMIP Dr. Oana Donea, medic primar oncolog cu supraspecializare in ingrijire paliativa Luciana Negulescu, asistent medical principal Alina Lazar, asistent social Activitatile

More information

CENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36)

CENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36) CENTER FOR CLINICAL TRIALS St. Luke s Medical Center Ongoing Clinical Trials CANCER INSTITUTE (36) BLOOD TITLE : A Randomized, Two By Two Arm, Multicenter, Open-Label Phase III Study Of BMS-354825 Administered

More information

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on

More information

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical

More information

National Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy

National Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and

More information

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled

More information

Spitalul Clinic Judetean de Urgenta str Clinicilor 3-5, , Cluj Napoca (Romania)

Spitalul Clinic Judetean de Urgenta str Clinicilor 3-5, , Cluj Napoca (Romania) Europass Curriculum Vitae Informatii personale Nume, Prenume (Nume anterior casatoriei: Padure ) Adresa Str. C.A.Rosetti, Nr. 16, Cluj Napoca (Romania) Telefon 0040745459080 E-mail(s) munteana2@yahoo.com

More information

Curriculum Vitae ARUN K. KALRA, MD

Curriculum Vitae ARUN K. KALRA, MD Curriculum Vitae ARUN K. KALRA, MD Office: CCARE California Cancer Associates in Research and Excellence 39755 Date St. Suite 103 Murrieta, California 92563 01/2017 to current. Arun Kalra MD Inc. 09/2016

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and

More information

Currently recruiting trials and/or near future recruitment

Currently recruiting trials and/or near future recruitment Clinical Trials at the Bank of Cyprus Oncology Centre (As of Jan 2018) Currently recruiting trials and/or near future recruitment Development of a module to supplement the EORTC Core instruments for assessment

More information

Nume / Prenume Negreanu Lucian Conferentiar Universitar Medician Interna si Gastroenterologie, Abilitat

Nume / Prenume Negreanu Lucian Conferentiar Universitar Medician Interna si Gastroenterologie, Abilitat Curriculum vitae Europass Informaţii personale Nume / Prenume Negreanu Lucian Conferentiar Universitar Medician Interna si Gastroenterologie, Abilitat Adresă(e) Spitalul UnivBucuresti, splaiul independentei

More information

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from

More information

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including

More information

Our Clinical Trials. Oncology

Our Clinical Trials. Oncology Our Clinical Trials Oncology ANGIOGENESIS Trebananib (AMG 86) (angiopoietin inhibitor) ANTIBODY DRUG CONJUGATE, continued AMG 595 (anti-egfrviii) Trebananib With Paclitaxel and Trastuzumab or Capecitabine

More information

Horizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma

Horizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology

More information

Vaccine Therapy for Cancer

Vaccine Therapy for Cancer Vaccine Therapy for Cancer Lawrence N Shulman, MD Chief Medical Officer Senior Vice President for Medical Affairs Chief, Division of General Oncology Dana-Farber Cancer Institute Disclosures for Lawrence

More information

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list. February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of

More information

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication. NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title

More information

IRB INDICATION Number ENROLLED

IRB INDICATION Number ENROLLED Revised 1/6/2011 OPEN TRIALS 2006-2011 INDICATION Number ENROLLED SPONSOR Title Provided Phase I AZA PH US 2007 PK 006 Celgene A Phase I, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics

More information

Roche setting the standards of cancer care Oncology Event for Investors, June 19

Roche setting the standards of cancer care Oncology Event for Investors, June 19 Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time

More information

NEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)

NEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650) NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/

More information

Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy

Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a

More information

The legally binding text is the original French version

The legally binding text is the original French version The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen

More information

European consortium study on the availability of anti-neoplastic medicines

European consortium study on the availability of anti-neoplastic medicines European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department

More information

National Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer

National Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Trastuzumab, as monotherapy and in combination with a taxane, for the treatment of metastatic breast cancer (to include

More information

Horizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887

Horizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a

More information

Jefferson Kimmel Cancer Center Network Presents: The Clinical Research E-News. January 14, 2009

Jefferson Kimmel Cancer Center Network Presents: The Clinical Research E-News. January 14, 2009 Jefferson Kimmel Cancer Center Network Presents: January 14, 2009 The Clinical Research E-News New Activations at TJU: NCCTG N0723: A Phase III Biomarker Validation Study of Second-Line Therapy in Patients

More information

Systemic Cytotoxic Therapy in advanced HCC

Systemic Cytotoxic Therapy in advanced HCC Systemic Cytotoxic Therapy in advanced HCC Yeul Hong Kim Korea University Anam Hospital Cancer Center Hepatocellular Carcinoma : Overview Epidemiology Current Guideline : advanced HCC Cytotoxic Chemotherapy

More information

Clinical Research in Rare Cancers. Friday 10 th February Matt Seymour & Nicola Keat

Clinical Research in Rare Cancers. Friday 10 th February Matt Seymour & Nicola Keat Clinical Research in Rare Cancers Friday 10 th February 2012 Matt Seymour & Nicola Keat Rare cancer is a common disease Rare Cancer : [prevalence

More information

Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2

Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles

More information

Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?

Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive

More information

Adjuvant Systemic Therapy in Early Stage Breast Cancer

Adjuvant Systemic Therapy in Early Stage Breast Cancer Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington

More information

Chemotherapy-induced HBV reactivation in cancer patients

Chemotherapy-induced HBV reactivation in cancer patients Chemotherapy-induced HBV reactivation in cancer patients On behalf of Taiwan Cooperative Oncology Group (TCOG) HBV reactivation in lymphoma patients: What we have known HBV reactivation and hepatitis flares

More information

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right

More information

Etudes cliniques Service d Oncologie - Radiothérapie

Etudes cliniques Service d Oncologie - Radiothérapie Etudes cliniques Service d Oncologie - Radiothérapie Mars 2017 SEIN ADJUVANT OLYMPIA : A Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant therapy in BRCA mutated

More information

NEWER DRUGS IN HEAD AND NECK CANCER. Prof. Anup Majumdar. HOD, Radiotherapy, IPGMER Kolkata

NEWER DRUGS IN HEAD AND NECK CANCER. Prof. Anup Majumdar. HOD, Radiotherapy, IPGMER Kolkata NEWER DRUGS IN HEAD AND NECK CANCER Prof. Anup Majumdar HOD, Radiotherapy, IPGMER Kolkata 1 Included Oral cavity Nasal cavity Pharynx Larynx Lymph node in upper part of neck Excluded Brain Eye Cancer arising

More information

Where Are Anti-Angiogenic Agents Positioned Within Cancer Care Guidelines?

Where Are Anti-Angiogenic Agents Positioned Within Cancer Care Guidelines? Introduction Additionally, other anti-angiogenic drugs, including sorafenib, sunitinib, axitinib, pazopanib, vandetanib, The development and subsequent use of drugs for treating cancer cabozantinib, and

More information

European Medicines Agency decision

European Medicines Agency decision EMA/738885/2013 European Medicines Agency decision P/0005/2014 of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for bevacizumab (Avastin), (EMEA-000056-PIP03-10-M02)

More information

Etudes cliniques Service d Oncologie - Radiothérapie

Etudes cliniques Service d Oncologie - Radiothérapie Etudes cliniques Service d Oncologie - Radiothérapie Juillet 2017 SEIN NEO ADJUVANT Neo-RHEA : NEOadjuvant Biomarker ResearcH Study of Palbociclib in Estrogen Receptor Positive HER2 Negative Breast CAncer

More information

Eribulin for locally advanced or metastatic breast cancer third line; monotherapy

Eribulin for locally advanced or metastatic breast cancer third line; monotherapy Eribulin for locally advanced or metastatic breast cancer third line; monotherapy April 2009 This technology summary is based on information available at the time of research and a limited literature search.

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: June 22, 2017 Avastin Description Avastin (bevacizumab)

More information

Breast Cancer Clinical Trials in Georgia

Breast Cancer Clinical Trials in Georgia www.georgiacore.org www.georgiatrials.org Breast Clinical Trials in Georgia Breast in Georgia: The Facts As the leading cause of cancer incidence among Georgia females, breast cancer accounts for 32 percent

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 20, 2018 Avastin Description Avastin

More information

European Medicines Agency decision

European Medicines Agency decision EMA/738884/2013 European Medicines Agency decision P/0004/2014 of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for bevacizumab (Avastin), (EMEA-000056-PIP01-07-M02)

More information

Working Formulary January 2013 Oncology Chemotherapy Regimens

Working Formulary January 2013 Oncology Chemotherapy Regimens Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy

More information

Updated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre)

Updated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre) Metastatic Esophagogastric Cancer Summary Updated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University

More information

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG

More information

Studies proceeding under pre HRA-Approval system (NHS Permission)

Studies proceeding under pre HRA-Approval system (NHS Permission) 15/NW/0004 162679 Studies proceeding under pre HRA-roval system (NHS Permission) A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST- LINE METASTATIC COLORECTAL

More information

Systemic Management of Breast Cancer

Systemic Management of Breast Cancer Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of

More information

COME HOME Innovative Oncology Business Solutions, Inc.

COME HOME Innovative Oncology Business Solutions, Inc. Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment

More information

All Studies by Indication

All Studies by Indication Therapeutic Area Protocol Number Drug/Device Phase Description Advanced malignancies 337 20101132 AMG 337 I " A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of

More information

The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium

The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive

More information

Long term survival in EGFR positive NSCLC patient. Dr.ssa G. Zago Oncologia Medica 2 Istituto Oncologico Veneto, IOV

Long term survival in EGFR positive NSCLC patient. Dr.ssa G. Zago Oncologia Medica 2 Istituto Oncologico Veneto, IOV Long term survival in EGFR positive NSCLC patient Dr.ssa G. Zago Oncologia Medica 2 Istituto Oncologico Veneto, IOV Medical history and diagnosis Male, caucasian 60 years old Former smoker (stop > 15 years)

More information

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)

More information

Scottish Medicines Consortium

Scottish Medicines Consortium P Oral) Scottish Medicines Consortium vinorelbine 20 and 30mg capsules (NavelbineP Pierre Fabre Ltd No. (179/05) 06 May 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

Ghiorghiu Ioana Adriana

Ghiorghiu Ioana Adriana Curriculum Vitae INFORMAŢII PERSONALE Ghiorghiu Ioana Adriana Bucuresti Scrieţi numărul de telefon Scrieţi numărul de telefon mobil Scrieţi adresa de email Scrieţi adresa paginii web personale Scrieţi

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy 11/13, 10/12, 11/11, 1, 6/10, Page 1 of 5 DESCRIPTION: Cetuximab is a recombinant humanized monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor

More information

Ovarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths

Ovarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths Management of Recurrent Ovarian Carcinoma Lee-may Chen, M.D. Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Comprehensive Cancer Center Ovarian Cancer Survival United States, 28: 1

More information

MEDICAL PRIOR AUTHORIZATION

MEDICAL PRIOR AUTHORIZATION MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 15, 2017 Avastin Description Avastin

More information

Dr. Cornelia NITIPIR. Curriculum vitae Europass. Informatii personale. Nume/Prenume: Adresa(e):... Telefon(oane):... Data nasterii: 16 iunie 1969

Dr. Cornelia NITIPIR. Curriculum vitae Europass. Informatii personale. Nume/Prenume: Adresa(e):... Telefon(oane):... Data nasterii: 16 iunie 1969 Curriculum vitae Europass Informatii personale Nume/Prenume: Dr. Cornelia NITIPIR Adresa(e):... Telefon(oane):... E-mail(uri): nitipir2003@yahoo.com Nationalitate (tati): Romaneasca Data nasterii: 16 iunie

More information

NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan

NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR

More information

Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications

Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications Kinga Malottki, Mousumi Biswas, Jon Deeks, Richard Riley, Charles Craddock, Lucinda Billingham

More information

Metastatic Breast Cancer What is new? Subtypes and variation?

Metastatic Breast Cancer What is new? Subtypes and variation? Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic

More information

Title Cancer Drug Phase Status

Title Cancer Drug Phase Status Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer

More information

Triple Negative Breast Cancer: Part 2 A Medical Update

Triple Negative Breast Cancer: Part 2 A Medical Update Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is

More information

TRANSPARENCY COMMITTEE OPINION. 15 February 2006

TRANSPARENCY COMMITTEE OPINION. 15 February 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial

More information

Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer

Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer * Substances without published evidence based on at

More information

GASTRIC & PANCREATIC CANCER

GASTRIC & PANCREATIC CANCER GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org

More information

Horizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line

Horizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available

More information

Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on and recommended the following:-

Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on and recommended the following:- Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on 05.11.2014 and recommended the following:- Agend a No. File No. 1. File No.: 12-75/13-DC Afatinib film coated tablet

More information

CLINICAL TRIALS ACC. Jul 2016

CLINICAL TRIALS ACC. Jul 2016 CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

More information

Targeted Therapies in Metastatic Colorectal Cancer: An Update

Targeted Therapies in Metastatic Colorectal Cancer: An Update Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab

More information

Tarceva. Tarceva (erlotinib) Description

Tarceva. Tarceva (erlotinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.82 Subject: Tarceva Page: 1 of 5 Last Review Date: June 22, 2018 Tarceva Description Tarceva (erlotinib)

More information

Etudes cliniques Service d Oncologie - Radiothérapie

Etudes cliniques Service d Oncologie - Radiothérapie Etudes cliniques Service d Oncologie - Radiothérapie Juillet 2016 SEIN-NEO ADJUVANT LORELEI -GO28888-1319 BCG : A phase II randomized, double-blind, parallel cohort study of neoadjuvant letrozole + GDC-0032

More information

Immunoconjugates in Both the Adjuvant and Metastatic Setting

Immunoconjugates in Both the Adjuvant and Metastatic Setting Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor

More information

My name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York.

My name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York. Welcome to this CME/CE-certified activity entitled, Integrating the Latest Advances Into Clinical Experience: Data and Expert Insights From the 2016 Meeting on Gastrointestinal Cancers in San Francisco.

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY CLINICAL MEDICAL POLICY Policy Name: Avastin (bevacizumab) Policy Number: MP-030-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective

More information

Horizon Scanning Technology Briefing. Cetuximab (Erbitux) for metastatic colorectal cancer. National Horizon Scanning Centre.

Horizon Scanning Technology Briefing. Cetuximab (Erbitux) for metastatic colorectal cancer. National Horizon Scanning Centre. Horizon Scanning Technology Briefing National Horizon Scanning Centre Cetuximab (Erbitux) for metastatic colorectal cancer December 2006 This technology summary is based on information available at the

More information

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please

More information

Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot

Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999

More information

Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy

Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic

More information

Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers

Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers Program 7:15 7:40 Translocations as predictive biomarkers in lung cancer: Overview Mari Mino Kenudson, MD 7:40 8:05 Translocation

More information

Summary of Research and Writing Activities in Oncology

Summary of Research and Writing Activities in Oncology Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,

More information

Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma

Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature

More information

Avastin Sample Coding

Avastin Sample Coding First- and Second-line Metastatic Colorectal Cancer C18.0 Malignant neoplasm of the cecum C18.1 Malignant neoplasm of appendix C18.2-C18.9 C19 C20 C21.8 Malignant neoplasm of the colon, various sites Malignant

More information

In prezent: Cercetator stiintiific grad III, medic primar gastroenterologie Centrul de Gastroenterologie si Hepatologie Institutul Clinic Fundeni

In prezent: Cercetator stiintiific grad III, medic primar gastroenterologie Centrul de Gastroenterologie si Hepatologie Institutul Clinic Fundeni CURRICULUM VITAE Nume: VĂDAN ROXANA Data naşterii: 3.05. 1970 Locul naşterii: Bucureşti Adresa (spital): Centrul de Gastroenterologie si Hepatologie, Institutul Clinic Fundeni; Soseaua Fundeni nr 258,

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.04 Subject: Avastin Page: 1 of 8 Last Review Date: December 3, 2015 Avastin Description Avastin (bevacizumab)

More information

Clinical Policy: Bevacizumab (Avastin) Reference Number: ERX.SPMN.127

Clinical Policy: Bevacizumab (Avastin) Reference Number: ERX.SPMN.127 Clinical Policy: (Avastin) Reference Number: ERX.SPMN.127 Effective Date: 03/14 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information